New immunotherapy cocktail aims to wipe out hidden colorectal cancer cells
NCT ID NCT07551596
First seen Apr 28, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This phase 2 trial tests whether combining two immunotherapy drugs, botensilimab and balstilimab, can clear tiny amounts of cancer DNA from the blood of patients with stage II or III colorectal cancer after standard treatment. The study enrolls 20 adults whose blood tests still show signs of cancer despite no visible tumors on scans. The goal is to see if the drug combination can eliminate these hidden cancer cells and prevent recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
botensilimab and balstilimab (immunotherapy drugs)
What this could lead to
If successful, this could show that combining these two immunotherapy drugs can eliminate remaining cancer cells in the blood, potentially reducing the risk of cancer returning.
What could go wrong
This is a small early-phase trial with only 20 participants, so results may not apply broadly. Immunotherapy can cause serious side effects like inflammation in healthy organs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.